Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBio-6517 +/- Pembrolizumab in Advanced Solid Tumors
NCT04301011Phase 1Terminated
- Sponsor
- Turnstone Biologics
- Start
- Jun 2020
- Primary completion
- Jan 2023
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 3
01
Overview
Phase 1, open-label trial of TBio-6517 in solid tumor (advanced stage), colorectal cancer (CRC), cholangiocarcinoma (CCA) and 3 more (8 arms), sponsored by Turnstone Biologics. Primary endpoints: Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) alone at 25 months, Incidence of adverse events when TBio-6517 administered by direct injection into tumor(s) when combined with pembrolizumab at 25 months and 3 more. Started Jun 2020; status: terminated.
02
Drugs
TBio-6517
03
Conditions
solid tumor (advanced stage)colorectal cancer (CRC)cholangiocarcinoma (CCA)cutaneous melanoma (CM)cutaneous squamous cell carcinoma (cSCC)
Beyond the preview
Go deeper on NCT04301011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04301011.